Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Neihulizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbGenomics Corporation
- 29 Nov 2018 Planned End Date changed from 1 Jan 2020 to 1 Sep 2020.
- 29 Nov 2018 Planned primary completion date changed from 1 Aug 2019 to 1 May 2020.
- 31 Aug 2018 Biomarkers information updated